Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 264

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Open access
Bryant, Andrew, Lawrie, Theresa A., Dowswell, Therese, Fordham, Edmund J., Mitchell, Scott, Hill, Sarah R., Tham, Tony C.·2021·American Journal of Therapeutics

Published version of a preprint

Abstract

Background: Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials. Areas of uncertainty: We assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection. Data sources: We searched bibliographic databases up to April 25, 2021. Two review authors sifted for studies, extracted data, and assessed risk of bias. Meta-analyses were conducted and certainty of the evidence was assessed using the GRADE approach and additionally in trial sequential analyses for mortality. Twenty-four randomized controlled trials involving 3406 participants met review inclusion. Therapeutic Advances: Meta-analysis of 15 trials found that ivermectin reduced risk of death compared with no ivermectin (average risk ratio 0.38, 95% confidence interval 0.19–0.73; n = 2438; I 2 = 49%; moderate-certainty evidence). This result was confirmed in a trial sequential analysis using the same DerSimonian–Laird method that underpinned the unadjusted analysis. This was also robust against a trial sequential analysis using the Biggerstaff–Tweedie method. Low-certainty evidence found that ivermectin prophylaxis reduced COVID-19 infection by an average 86% (95% confidence interval 79%–91%). Secondary outcomes provided less certain evidence. Low-certainty evidence suggested that there may be no benefit with ivermectin for “need for mechanical ventilation,” whereas effect estimates for “improvement” and “deterioration” clearly favored ivermectin use. Severe adverse events were rare among treatment trials and evidence of no difference was assessed as low certainty. Evidence on other secondary outcomes was very low certainty. Conclusions: Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/mjt.0000000000001402

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 68 references

Research works printed but not linked: 15

  1. Banerjee, 2020, The battle against covid 19 pandemic: what we need to know before we “test fire” ivermectin, Drug Res (Stuttg)., 70, 337, 10.1055/a-1185-8913 · doi:10.1055/a-1185-8913
  2. DiNicolantonio, 2020, Ivermectin may be a clinically useful anti-inflammatory agent for late-stage covid-19, Open Heart., 7, e001350, 10.1136/openhrt-2020-001350 · doi:10.1136/openhrt-2020-001350
  3. Elgazzar, 2020, Efficacy and safety of ivermectin for treatment and prophylaxis of covid-19 pandemic, Res Square.
  4. Bernigaud, 2021, Oral ivermectin for a scabies outbreak in a long‐term–care facility: potential value in preventing COVID‐19 and associated mortality?, Br J Dermatol., 10.1111/bjd.19821 · doi:10.1111/bjd.19821
  5. Espitia-Hernandez, 2020, Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: a proof of concept study, Biomed Res., 31, 129
  6. Morgenstern, 2020, The use of compassionate ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of covid-19 at the medical center bournigal and the medical center punta cana, rescue group, Dominican Republic, medRxiv
  7. Ravikirti, 2021, Ivermectin as a potential treatment for mild to moderate COVID-19 - a double blind randomized placebo-controlled trial, medRxiv.
  8. Yagisawa, 2021, Global trends in clinical studies of ivermectin in COVID-19, Jpn J Antibiot., 74, 44
  9. Nardelli, 2021, Crying wolf in time of Corona: the strange case of ivermectin and hydroxychloroquine. Is the fear of failure withholding potential life-saving treatment from clinical use?, Signa Vitae., 17, 3
  10. Carvallo, 2020, Study of the efficacy and safety of topical ivermectin + iona-Carrageenan in the prophylaxis against COVID-19 in health personnel, J Biomed Res Clin Invest., 2, 1007
  11. Behera, 2021, Prophylactic role of ivermectin in SARS-CoV-2 infection among healthcare workers, Res Square.
  12. Chowdhury, 2020, A randomized trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients, Res Square.
  13. Schwartz, 2021, Viral load and culture viability in mild COVID-19 patients treated with Ivermectin, New England J Med.
  14. Chahla, 2021, A randomized trial: intensive treatment based in Ivermectin and iota-Carageenan as pre-exposure prophylaxis for COVID-19 in healthcare agents, medRxiv
  15. Shouman, 2021, Use of ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt: a randomized clinical trial, J Clin Diagn Res., 15, OC27

Cited by

See all 264

Metadata

Authors
Bryant, A., Lawrie, T. A., Dowswell, T., Fordham, E. J., Mitchell, S., Hill, S. R., & Tham, T. C.
Venue
American Journal of Therapeutics
Published
2021-06-21
Volume
28
Issue
4
Pages
e434-e460
ISSN
1075-2765 (ISSN-L)
OpenAlex
W3168908540
Cited by
264
References
68
FWCI
8.19
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. https://app.cochat.ai/papers/10.1097/mjt.0000000000001402
The paper
Bryant, A., Lawrie, T. A., Dowswell, T., Fordham, E. J., Mitchell, S., Hill, S. R., & Tham, T. C. (2021). Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0000000000001402

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.